Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as in contrast with imatinib, for the initial-line treatment of CML-CP. Five hundred and nineteen patients with newly diagnosed CML-CP have been randomly assigned to obtain dasatinib at a dose of one hundred mg the moment daily (259 patients) https://marcoswaej.blogminds.com/considerations-to-know-about-xmu-mp-1-26477094